NU SKIN ENTERPRISES, INC. Depreciation
NU SKIN ENTERPRISES, INC. (NUS) reported Depreciation of $43.90 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-02-13
- NU SKIN ENTERPRISES, INC. depreciation for fiscal 2025 was $43.90M, a 21.89% decline from fiscal 2024.
- NU SKIN ENTERPRISES, INC. depreciation for fiscal 2024 was $56.20M, a 2.60% decline from fiscal 2023.
- NU SKIN ENTERPRISES, INC. depreciation for fiscal 2023 was $57.70M, a 5.41% decline from fiscal 2022.
- NU SKIN ENTERPRISES, INC. depreciation for fiscal 2022 was $61.00M, a 3.02% decline from fiscal 2021.
| Period end | Depreciation 12 month |
|---|---|
| 2025-12-31 | $43.90M 10-K · filed 2026-02-13 |
| 2024-12-31 | $56.20M 10-K · filed 2026-02-13 |
| 2023-12-31 | $57.70M 10-K · filed 2026-02-13 |
| 2022-12-31 | $61.00M 10-K · filed 2025-02-14 |
| 2021-12-31 | $62.90M 10-K · filed 2024-02-15 |
| 2020-12-31 | $62.50M 10-K · filed 2023-02-16 |
| 2019-12-31 | $61.70M 10-K · filed 2022-02-16 |
| 2018-12-31 | $56.40M 10-K · filed 2021-02-11 |
| 2017-12-31 | $58.30M 10-K · filed 2020-02-13 |
| 2016-12-31 | $60.80M 10-K · filed 2019-02-14 |
| 2015-12-31 | $61.60M 10-K · filed 2018-02-16 |
| 2014-12-31 | $46.50M 10-K · filed 2017-02-27 |
| 2013-12-31 | $27.10M 10-K · filed 2016-02-18 |
| 2012-12-31 | $25.50M 10-K · filed 2015-03-02 |
| 2011-12-31 | $25.70M 10-K · filed 2014-03-18 |
| 2010-12-31 | $22.70M 10-K · filed 2013-02-27 |
| 2009-12-31 | $21.80K 10-K · filed 2012-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cosmos Health Inc. (COSM) | Greece | $0.038B | -0.60 |
| HWH International Inc. (HWH) | United States | $0.021B | -4.08 |
| DataMeds AI, Inc. (MEDS) | United States | $0.011B | |
| HERBALIFE LTD. (HLF) | $1.281B | 8.39 | |
| CARDINAL HEALTH INC (CAH) | United States | $51.753B | 29.38 |
| Cencora, Inc. (COR) | United States | $59.130B | 20.57 |
| MCKESSON CORP (MCK) | United States | $101.317B | 19.78 |